Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial

What Was Tested

The paper reports a study of Tesamorelin and GHRH (Growth Hormone-Releasing Hormone), published as a randomized controlled trial.

To investigate the effect of tesamorelin on visceral and liver fat.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Double-blind, randomized, placebo-controlled trial conducted among 50 antiretroviral-treated HIV-infected men and women with abdominal fat accumulation at Massachusetts General Hospital in Boston.

The first patient was enrolled on January 10, 2011; for the final patient, the 6-month study visit was completed on September 6, 2013.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Tesamorelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Tesamorelin.

The comparison arm used a placebo, so changes seen with Tesamorelin could be set against what happens without it.

What Was Measured

The subject headings attached to it are Abdominal Fat, Adiposity, Fatty Liver, Growth Hormone-Releasing Hormone, HIV Infections, Intra-Abdominal Fat and Liver.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tesamorelin and GHRH (Growth Hormone-Releasing Hormone).

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (JAMA), a journal based in United States.

More context: the Tesamorelin compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page.